Citation Impact
Citing Papers
Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment
2013 Standout
Hirsutism and oligomenorrhea are appropriate screening criteria for polycystic ovary syndrome in adolescents
2015
Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan
2010 Standout
Recommendations from the international evidence‐based guideline for the assessment and management of polycystic ovary syndrome
2018 Standout
Longitudinal assessment of antimüllerian hormone during pregnancy—relationship with maternal adiposity, insulin, and adiponectin
2009
Anti-Müllerian hormone (AMH): Regulator and marker of ovarian function
2010
Differential Expression of the Angiogenic Factor Genes Vascular Endothelial Growth Factor (VEGF) and Endocrine Gland-Derived VEGF in Normal and Polycystic Human Ovaries
2003
The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
2004 Standout
High reproducibility of serum anti-Müllerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status
2005
Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high?
2010
What is polycystic ovary syndrome?: Are national views important?
2002
Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society
2011
Serum anti-Mullerian hormone levels are negatively related to Follicular Output RaTe (FORT) in normo-cycling women undergoing controlled ovarian hyperstimulation
2010
What is polycystic ovarian syndrome?: A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome
2002
Comparison of serum anti-Müllerian hormone levels in normal weight and overweight–obese adolescent patients with polycystic ovary syndrome
2014
Changes in anti-Mullerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility
2004
Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome
2007
Diagnosis of Polycystic Ovarian Syndrome: The Rotterdam Criteria Are Premature
2006
Is the plasma anti-Müllerian hormone (AMH) level associated with body weight and metabolic, and hormonal disturbances in women with and without polycystic ovary syndrome?
2011
A 27-Year-Old Woman With a Diagnosis of Polycystic Ovary Syndrome
2007
Anti-Mullerian hormone in the diagnosis of polycystic ovary syndrome: can morphologic description be replaced?
2012
Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study
2002
A Functional Anti-Müllerian Hormone Gene Polymorphism Is Associated with Follicle Number and Androgen Levels in Polycystic Ovary Syndrome Patients
2008
Serum antimullerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS)
2010
Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment
2018 Standout
Ovarian size and response to laparoscopic ovarian electro‐cauterization in polycystic ovarian disease
2001
Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism
2005
Ranibizumab for Neovascular Age-Related Macular Degeneration
2006 Standout
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
2004 Standout
Normal serum anti-Müllerian hormone levels in the general female population and the relationship with reproductive history
2012
Diagnosis and treatment of polycystic ovarian syndrome in adolescents
2012
Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries
2011
MetforminVersusEthinyl Estradiol-Cyproterone Acetate in the Treatment of Nonobese Women with Polycystic Ovary Syndrome: A Randomized Study
2003
Rethinking mechanisms, diagnosis and management of endometriosis
2019 Standout
New insights into nNOS regulation of vascular homeostasis
2005 StandoutNobel
The Thrombospondins
2011 Standout
Prevalence of the Polycystic Ovary Syndrome in Unselected Black and White Women of the Southeastern United States: A Prospective Study1
1998 Standout
Clinical uses of anti-Müllerian hormone assays: pitfalls and promises
2008
The physiology and clinical utility of anti-Müllerian hormone in women
2014 Standout
Angiogenesis: an organizing principle for drug discovery?
2007 Standout
Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome
2004
Anti-Mullerian hormone is increased in follicular fluid from unstimulated ovaries in women with polycystic ovary syndrome
2008
Expression of Vascular Endothelial Growth Factor Receptor 1 in Bone Marrow-derived Mesenchymal Cells Is Dependent on Hypoxia-inducible Factor 1
2006 StandoutNobel
The biology of VEGF and its receptors
2003 Standout
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
2006 Standout
Endocrine consequences of premature pubarche in post‐pubertal Caucasian girls
2002
Polycystic Ovaries Are Common in Women with Hyperandrogenic Chronic Anovulation but Do Not Predict Metabolic or Reproductive Phenotype
2005
Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts
2009
Updated ultrasound criteria for polycystic ovary syndrome: reliable thresholds for elevated follicle population and ovarian volume
2013
Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
2013 Standout
Obesity
2005 Standout
Polycystic ovarian syndrome during puberty and adolescence
2013
Anti-Müllerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels
2008
EG-VEGF and Bv8: a novel family of tissue-restricted angiogenic factors
2003
Antimüllerian hormone levels decrease in women using combined contraception independently of administration route
2012
Is polycystic ovary syndrome an exception for reproductive aging?
2010
The degree of cycle irregularity correlates with the grade of endocrine and metabolic disorders in PCOS patients
2010
PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO‐II anovulation and association with metabolic factors
2006
Polycystic ovarian morphology in adolescents with regular menstrual cycles is associated with elevated anti-Mullerian hormone
2011
Results of an Open One‐Year Study with Diane‐35 in Women with Polycystic Ovarian Syndrome
1993
Circulating basal anti-Müllerian hormone levels as predictor of ovarian response in women undergoing ovarian stimulation for in vitro fertilization
2008
Heritability and the risk of developing androgen excess
1999
Serum Anti-Müllerian hormone (AMH) levels are differentially modulated by both serum gonadotropins and not only by serum Follicle Stimulating Hormone (FSH) levels
2011
Müllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture
2007
Vascular endothelial growth factor in eye disease
2008 Standout
Long-term follow-up of patients with polycystic ovary syndrome: reproductive outcome and ovarian reserve
2009
Measuring anti-Müllerian hormone for the assessment of ovarian reserve: When and for whom is it indicated?
2011
Fertility and infertility: Definition and epidemiology
2018 Standout
8 Definition and significance of polycystic ovaries
1997
Oligoanovulation with Polycystic Ovaries But Not Overt Hyperandrogenism
2006
The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report
2008 Standout
The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest
2004
Is foetal hyperexposure to androgens a cause of PCOS?
2017
Effects of transdermal testosterone application on the ovarian response to FSH in poor responders undergoing assisted reproduction technique—a prospective, randomized, double-blind study
2006
Ultrasound assessment of the polycystic ovary: international consensus definitions
2003
Association of anti-mullerian hormone levels with obesity in late reproductive-age women
2006
The Role of Ovarian Volume As a Diagnostic Criterion for Chinese Adolescents with Polycystic Ovary Syndrome
2008
The role of serum anti-Müllerian hormone (AMH) in the hormonal diagnosis of polycystic ovary syndrome
2013
Endocrine and Metabolic Effects of MetforminVersusEthinyl Estradiol-Cyproterone Acetate in Obese Women with Polycystic Ovary Syndrome: A Randomized Study1
2000
Polycystic Ovary Syndrome
2005 Standout
New Approach to Polycystic Ovary Syndrome and Other Forms of Anovulatory Infertility
2002
Elevated serum anti-Müllerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features
2012
Serum Anti-Müllerian Hormone as a Surrogate for Antral Follicle Count for Definition of the Polycystic Ovary Syndrome
2006
The Pregnancy in Polycystic Ovary Syndrome Study: baseline characteristics of the randomized cohort including racial effects
2006
Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS
2007
Ovarian suppression with triptorelin and adrenal stimulation with adrenocorticotropin in functional hyperadrogenism: role of adrenal and ovarian cytochrome P450c17α
1994
The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance
2016
Does AMH Reflect Follicle Number Similarly in Women with and without PCOS?
2016
Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth
2005
Ultrasound diagnosis of polycystic ovaries in women who have no symptoms of polycystic ovary syndrome is not associated with subfecundity or subfertility
2003
Severe ureteral endometriosis: the intrinsic type is not so rare after complete surgical exeresis of deep endometriotic lesions
2009
Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group
2011 Standout
A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio
2001
Lifecycle of Polycystic Ovary Syndrome (PCOS): From In Utero to Menopause
2013
Adrenalectomy for a Solitary Adrenal Metastasis From Lung Cancer
1998
Thrombospondin‐1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor‐related protein‐1 (LRP‐1)
2006
Anti-Mullerian hormone (AMH): what do we still need to know?
2009
Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome
1997
Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome?
2012
The phenotype of polycystic ovary syndrome ameliorates with aging
2011
Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART)
2009
Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome
2005
Polycystic ovary syndrome
2016 Standout
ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria
2011 Standout
Prevalence and Predictors of Risk for Type 2 Diabetes Mellitus and Impaired Glucose Tolerance in Polycystic Ovary Syndrome: A Prospective, Controlled Study in 254 Affected Women1
1999 Standout
Can Anti-Müllerian Hormone Predict the Diagnosis of Polycystic Ovary Syndrome? A Systematic Review and Meta-Analysis of Extracted Data
2013
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
2015 Standout
Anti-Müllerian hormone and ovarian dysfunction
2008
The diagnosis of polycystic ovary syndrome in adolescents
2010
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
2006 Standout
Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes
2010
Ultrasound examination of polycystic ovaries: is it worth counting the follicles?
2003
Angiogenesis as a therapeutic target
2005 StandoutNature
A single test of antimüllerian hormone in late reproductive-aged women is a good predictor of menopause
2009
Effect of Obesity on Parameters of Ovarian Reserve in Premenopausal Women
2010
High prevalence of polycystic ovary syndrome in women with mild hirsutism and no other significant clinical symptoms
2009
An evaluation of the inter-observer and intra-observer variability of the ultrasound diagnosis of polycystic ovaries
2002
Is the PCOS diagnosis solved by ESHRE/ASRM 2003 consensus or could it include ultrasound examination of the ovarian stroma?
2006
PCOS Forum: research in polycystic ovary syndrome today and tomorrow
2010
Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society
2013
The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria
2009 Standout
Anti-Mullerian hormone: a new marker for ovarian function
2005
Wound repair and regeneration: Mechanisms, signaling, and translation
2014 Standout
Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty.
1976 Standout
Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline
2006 Standout
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
2004 Standout
Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism.
1993
Polycystic Ovary-Like Abnormalities (PCO-L) in Women with Functional Hypothalamic Amenorrhea
2012
Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement
2009 Standout
Ovarian imaging by magnetic resonance in adolescent girls with polycystic ovary syndrome and age‐matched controls
2013
Variations in the Pattern of Pubertal Changes in Boys
1970 Standout
Serum Anti-Mullerian Hormone Concentrations Are Elevated in Oligomenorrheic Girls without Evidence of Hyperandrogenism
2010
Anti-Mullerian Hormone Protein Expression Is Reduced during the Initial Stages of Follicle Development in Human Polycystic Ovaries
2005
Hormonal Profile in Women with Polycystic Ovarian Syndrome with or without Type 1 Diabetes Mellitus
2007
Increased Oocyte Degeneration and Follicular Atresia during the Estrous Cycle in Anti-Mullerian Hormone Null Mice
2007
Anti-Mullerian Hormone Levels in Peripubertal Daughters of Women with Polycystic Ovary Syndrome
2007
Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome
2015
A rational approach to the diagnosis of polycystic ovarian syndrome during adolescence
2011
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
2011 Standout
Stromal Cell–Derived Factor-1α and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor
2005 StandoutNobel
A Prospective Study of the Prevalence of the Polycystic Ovary Syndrome in Unselected Caucasian Women from Spain1
2000 Standout
Characterization of Functionally Typical and Atypical Types of Polycystic Ovary Syndrome
2009
The Metabolic Syndrome
2008 Standout
Insulin Resistance and the Polycystic Ovary Syndrome Revisited: An Update on Mechanisms and Implications
2012 Standout
Changes in Serum Anti-Mullerian Hormone Level during Low-Dose Recombinant Follicular-Stimulating Hormone Therapy for Anovulation in Polycystic Ovary Syndrome
2007
Physiological Aspects of Female Fertility: Role of the Environment, Modern Lifestyle, and Genetics
2016
Anti-Müllerian hormone and anti-Müllerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women
2007
Criteria for Polycystic Ovarian Morphology in Polycystic Ovary Syndrome as a Function of Age
2009
Anti-Mullerian Hormone, Its Receptor, FSH Receptor, and Androgen Receptor Genes Are Overexpressed by Granulosa Cells from Stimulated Follicles in Women with Polycystic Ovary Syndrome
2008
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Works of Yann Robert being referenced
Ovarian stromal hypertrophy in hyperandrogenic women
1994
Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries
2005
Polycystic ovarian disease: contribution of vaginal endosonography and reassessment of ultrasonic diagnosis
1991
[Ureteric and bladder involvement of deep pelvic endometriosis. Value of multidisciplinary surgical management].
2006
Ultrasound assessment of ovarian stroma hypertrophy in hyperandrogenism and ovulation disorders: visual analysis versus computerized quantification
1995
What are the determinants of the antral follicle number at ovarian ultrasonography (U/S) in PCOS?
2003
CT-guided biopsy of adrenal masses in preoperative management of bronchogenic carcinoma
1994
Elevated Serum Level of Anti-Mullerian Hormone in Patients with Polycystic Ovary Syndrome: Relationship to the Ovarian Follicle Excess and to the Follicular Arrest
2003